Beyond Small Molecules: Addressing Nitrosamine Challenges in Next-Generation Biotherapeutics

We, 25.11.2026 07:00 CET
Facing xenobiotic impurity and nitrosamine risks in complex biotherapeutics? Discover advanced LC-MS strategies to ensure EMA Article 5(3) compliance.
Agilent Technologies: Beyond Small Molecules: Addressing Nitrosamine Challenges in Next-Generation Biotherapeutics
Agilent Technologies: Beyond Small Molecules: Addressing Nitrosamine Challenges in Next-Generation Biotherapeutics

INSIDE IMPURITIES: ASK THE EXPERT

Episode 2 | Beyond Small Molecules: Addressing Impurities Challenges in Next-Generation Biotherapeutics

As drug development moves into more complex modalities, is the impurities conversation changing with it?

Inside Impurities: Ask the Expert is a new expert-led webinar series exploring the regulatory, analytical and practical challenges shaping pharmaceutical impurity management.

Following our first episode on India's evolving nitrosamine regulatory landscape, Episode 2 takes the conversation beyond traditional small-molecule drugs.

What happens when xenobiotic impurities risk enters the world of biotherapeutics?

As pipelines expand across biologics, peptides and oligonucleotides, pharmaceutical and biopharmaceutical teams need to understand where xenobiotic impurities risks may arise, how those risks should be assessed, and how analytical strategies can support confident impurity characterization.

Join Dr. Sanjib Banerjee, COO, Veeda Lifesciences, and Ashish Pargaonkar, Market Specialist – Biopharma, Agilent, for an expert-led discussion on emerging impurities challenges in next-generation therapeutics.

What we'll explore
  • How impurities concerns are evolving beyond traditional small molecules
     
  • Potential formation pathways in biologics, oligonucleotides and peptide therapeutics
     
  • Current and emerging regulatory expectations for risk assessment and control
     
  • Practical approaches to identifying, monitoring and mitigating xenobiotic impurities risks
     
  • Advanced LC-MS-based analytical approaches for trace impurity detection and characterization
     
  • How organizations can proactively prepare for evolving regulatory requirements, including developments such as the EMA Article 5(3) review
Why this matters

For teams working across analytical development, QC, process development and regulatory affairs, the challenge is not simply whether a xenobiotic impurity can be detected.

It is understanding where the risk may originate, how to characterize it confidently, and how to build a control strategy that can keep pace with evolving regulatory expectations.

This session will bring an industry and analytical perspective to those questions, with practical insights for teams developing and testing next-generation therapeutics.

Bring your questions

Have a question about impurities risk in your modality, analytical strategy or regulatory approach?

Submit your question when you register or ask it live during the Q&A.

Presenter: Dr. Sanjib Banerjee (Chief Operating Officer - Biopharma Services, Veeda Lifesciences)

Dr. Sanjib Banerjee, currently serving as Chief Operating Officer of biopharma services, has successfully established Veeda’s Biopharma business and other resources in Bengaluru (India). The Biopharma division of Veeda Lifesciences is serving biologics clientele globally with CRDMO-type services, serving as a Centre of Excellence for the analytical characterization of biologics.

Dr. Sanjib Banerjee, is a Cell Biologist and Immunologist with 20+ years of research and industrial experience in biologics, biosimilars and vaccines. Dr. Sanjib has been instrumental in establishing best-in-class regulated laboratories for immunological and serological characterization of biosimilars and vaccines for multiple different organizations. He has been in a technical leadership roles in CMC, biologics and vaccine characterisation and clinical research for 10+ regulatory submissions along with CRO management for preclinical and clinical studies.

He has postdoctoral experience on Cellular Biophysics of oncology/aging-related diseases in humans (Department of Biochemistry and Molecular Biology, University of Texas), and in Tumour Immunology and Biomarker studies in solid tumour (Department of Surgery, University of Rochester, NY). Dr. Sanjib Banerjee secured his Ph.D in Epigenetics from the Indian Institute of Chemical Biology, Kolkata. 

Presenter: Ashish Pargaonkar, Ph.D. (Biopharma Applications Specialist, Agilent Technologies)

Dr. Ashish Pargaonkar is a Lead for Biopharma Workflow Commercialization team for India and also Manager for Centre of Excellences at Bangalore. A Microbiologist by education with a Ph.D, he holds more than 20 years of experience for Biopharma market applications on Hi Resolution Mass Spectrometry.

He has a long record of successful demonstrations and customer engagements on workflows for CQA’s, Intact mass, peptide mapping, HCP and Glycans using Agilent state-of-the art solutions. He has authored ASMS posters on media components and therapeutic peptides. Dr. Ashish has been invited speaker at several conferences and workshops at Biosimilar Congress, ADC 2018, IIT (Mumbai, Delhi), ICT (Mumbai), PSI events.

Agilent Technologies
LinkedIn Logo